EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Predicting recurrence and survival in patients with laryngeal cancer by means of DNA cytometry, tumor front grading, and proliferation markers



Predicting recurrence and survival in patients with laryngeal cancer by means of DNA cytometry, tumor front grading, and proliferation markers



Annals of Otology, Rhinology, and Laryngology 104(7): 503-510



The cure rates for squamous cell carcinoma of the larynx have improved little over the past few decades. Despite the large number of therapeutic and histopathologic studies that have been performed, there are currently no morphologic or cytologic markers available to predict outcome in patients with laryngeal cancer. In an attempt to create such a system, tissues from 40 patients who underwent surgery for carcinoma of the larynx were examined for this pilot study. The examinations included routine histology, morphologic grading at the tumor front, immunohistochemical identification of the proliferation markers proliferating cell nuclear antigen (PCNA) and Ki67, and quantitative DNA analysis. By means of the stepwise multivariate Cox regression analysis with forward selection, factors that were highly correlated to the development of recurrent disease and survival were determined. We found that the results of the DNA analysis (ie, 2c deviation index, DNA malignancy grade), along with the morphologic tumor front grading and Ki67 score, were closely related to prognosis (p < .01). All of these factors reflect tumor biology. No correlation was found for the Broders grading or for any other clinical parameter. With the test battery used in this preliminary study, patients at high risk for developing tumor recurrences could be recognized. The advantages of this technique are that it is an objective assessment of the tumor and that it can be performed on preoperative biopsy specimens. This might influence decisions regarding therapeutic management and could eventually lead to more appropriate and individualized therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 009227142

Download citation: RISBibTeXText

PMID: 7598360

DOI: 10.1177/000348949510400701



Related references

Tumor front grading in prediction of survival and lymph node metastases in patients with laryngeal carcinoma. Advances in Medical Sciences 51(): 200-204, 2007

Clinical application of proliferation marker PCNA, protein p53 and tumour front grading analysis in patients operated due to laryngeal cancer. European Archives of Oto-Rhino-Laryngology 255(SUPPL 1): S18, 1998

Impact of flow cytometry on predicting recurrence and survival in breast cancer patients. Breast Cancer Research and Treatment 5(2): 117-128, 1985

Emerging Impact of Flow Cytometry in Predicting Recurrence and Survival in Breast Cancer Patients. Journal of Urology 135(4): 888-889, 1986

Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients. Journal of the National Cancer Institute 75(3): 405-410, 1985

Clinical application of proliferating cell nuclear antigen, oncoprotein p53 and tumor front grading analysis in patients operated on for laryngeal cancer. European Archives of Oto-Rhino-Laryngology 256(8): 378-383, Sept, 1999

The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Diseases of the Colon and Rectum 48(12): 2197-2208, 2006

Measurement of DNA content and ploidy and proliferation markers-protein p53 and PCNA in survival prognosing in patients operated due to laryngeal cancer. Pathology Research & Practice 193(5-6): 407, 1997

Predicting tumor metastasis in patients with oral cancer by means of the proliferation marker Ki67. Journal of Oral Science 41(2): 53-56, 1999

NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clinical Cancer Research 13(23): 7044-7052, 2007

Peritoneal and serum tumor markers predict recurrence and survival of patients with resectable gastric cancer. Gastric Cancer 2(1): 1-7, 1999

Peritoneal and serum tumor markers predict recurrence and survival of patients with resectable gastric cancer. Gastric Cancer 2(1): 1-7, 2002

Immunohistochemical analysis of carcinoma microenvironment antigens in tumour front grading in patients operated due to laryngeal cancer. Pathology Research & Practice 193(5-6): 408, 1997

Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior. Cancer 86(8): 1583-1589, Oct 15, 1999

Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research 23(11): 2681-2690, 2016